Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03848754 · ClinicalTrials.gov registry record · Phase 1
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03848754 is a Phase 1 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 14 participants.
The verdict
NCT03848754, a Phase 1 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a prospective, single-center phase 1 clinical study aimed at determining the maximum-tolerated dose and safety of the combination of gemtuzumab ozogamicin (GO) and pracinostat (P) in patients with relapsed/refractory acute myeloid leukemia.
Interventions
- DRUG Gemtuzumab Ozogamicin 3 mg/m^2
- DRUG Gemtuzumab Ozogamicin 2 mg/m^2
- DRUG Pracinostat - 45 mg
- DRUG Pracinostat - 60 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-05-24 |
| Est. Completion | 2021-05-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03848754
The ClinicalTrials.gov registry entry for NCT03848754 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gemtuzumab Ozogamicin 3 mg/m^2 is the first listed.
NCT03848754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03848754 about?
NCT03848754 is a clinical study titled "Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia". This is a prospective, single-center phase 1 clinical study aimed at determining the maximum-tolerated dose and safety of the combination of gemtuzumab ozogamicin (GO) and pracinostat (P) in patients with relapsed/refractory acute myeloid leukemia.
What is the current status of trial NCT03848754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-05-24. Estimated completion is 2021-05-05.
What interventions are being tested in trial NCT03848754?
The interventions under investigation include: Gemtuzumab Ozogamicin 3 mg/m^2 (DRUG), Gemtuzumab Ozogamicin 2 mg/m^2 (DRUG), Pracinostat - 45 mg (DRUG), Pracinostat - 60 mg (DRUG).
Who is sponsoring clinical trial NCT03848754?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.